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Summary The c-erbB-2 gene is overexpressed in about 20% of human breast cancers. Four hundred and
eighty-three cases previously examined by immunohistochemical staining for c-erbB-2 expression were analysed
to assess the risk associated with the elevated protein expression. Oncoprotein expression was correlated with
increasing tumour grade but not with oestrogen receptor status, nodal involvement, tumour size or age. There
was an increased risk of relapse and death associated with c-erbB-2 expression irrespective of nodal involve-
ment. This marker thus appears to be a significant prognostic factor in the early as well as the late stages of
breast cancer.
The c-erbB-2 protein is closely related in structure to the
epidermal growth factor receptor and is a member of a large
family of cell surface growth factor receptors (Hanks et al.,
1988). No natural ligand has been characterised in detail
which binds to c-erbB-2 although one report has described a
mitogenic activity apparently acting through the c-erbB-2
protein (Yarden & Weinberg, 1989). However, c-erbB-2 is
likely to act functionally as a growth factor receptor since
under certain conditions it is capable of conveying a mito-
genic signal (Lehvaslaiho et al., 1989; Lee et al., 1989).
The protein is present in a wide variety of cell types in a
range of normal humal foetal and adult tissues (Quirke et al.,
1989). Either mutation of a specific residue in c-erbB-2 which
causes receptor aggregation and tyrosine kinase activation, or
elevated expression of the normal c-erbB-2 protein can trans-
form cells in culture (Gullick & Venter, 1989). The mutant
protein is also a remarkably powerful oncogene in transgenic
animals (Muller et al., 1988; Bouchard et al., 1989). Over-
expression of the c-erbB-2 protein occurs frequently, gener-
ally as a consequence of gene amplification, in human breast
(Slamon et al., 1989), stomach (Falck & Gullick, 1989), and
ovarian cancers (Slamon et al., 1989). Reports also exist of
gene amplification in some pancreatic, colonic, renal and
salivary gland tumours (Gullick & Venter, 1989). c-erbB-2
protein levels are elevated in the great majority of the rapidly
growing variant of breast ductal carcinoma in situ of the
large cell, comedo type (Van de Vijver et al., 1988).
The presence of high levels of c-erbB-2 in breast and
ovarian cancers has been reported to be associated with poor
relapse free survival and overall survival (Slamon et al., 1989;
Van de Vijver et al., 1988; Wright et al., 1989; Varley et al.,
1987; Walker et al., 1989; Tsuda et al., 1989; Tandon et al.,
1989; Lovekin et al., 1989; Dolan et al., 1989; Cline et al.,
1987). Others have not observed a statistically significant
relationship in breast cancer (Gusterson et al., 1988; Ali et
al., 1988; Zhou et al., 1989; Barnes et al., 1988) although a
trend has been observed. In two reports c-erbB-2 overexpres-
sion could not be demonstrated to be associated with poor
prognosis in node negative breast cancer patients, where it
would be potentially of most value clinically (Slamon et al.,
1989; Tandon et al., 1989). A major criticism of almost all of
these analyses is the limited number of cases examined com-
bined with the low frequency (about 20%) of elevated c-
erbB-2 expression and the survival of about half of the
patients, making confident statistical statements difficult.
Previously, we have published three studies examining
c-erbB-2 protein expression in breast cancer and its value as a
predictive indicator. One study (Wright et al., 1989) showed
a strong predictive value of c-erbB-2 overexpression but the
other two (Gusterson et al., 1988; Barnes et al., 1988) did
not. Here we combine the data from these studies to provide
a total of 483 cases and show that c-erbB-2 overexpression
does provide an independent marker for poor relapse free
survival and overall survival in breast cancer patients inde-
pendent of node status.
Materials and methods
All three studies were carried out using antibody 21N on
formalin-fixed, paraffin-embedded sections from patients with
primary breast cancer. 21N is a polyclonal antibody raised
against a synthetic peptide sequence from the c-terminus of
the predicted oncoprotein (residue 1243-1255) (Gullick et
al., 1987). In the Guy's study (Barnes et al., 1988) infiltrating
carcinomas from 195 women were examined. These were
chosen to include nearly equal numbers of node positive and
node negative women, both with and without recurrence at
the time of the study. Up to 10 years of follow-up data were
available. A peroxidase conjugated avidin-biotin complex
technique was used.
One hundred and three patients with infiltrating carcin-
oma, of whom 57 had lymph node metastases, were studied
by the Royal Marsden group (Gusterson et al., 1988). The
patients were chosen to include those who had relapsed
within 1 year and those who remained disease-free at 5 years.
Immunocytochemical staining was carried out with an in-
direct immunoperoxidase technique.
The Newcastle group (Wright et al., 1989) stained tissue
from 185 primary breast carcinomas collected from con-
secutive patients over a 50-month period, using a peroxidase
conjugated streptavidin-biotin complex technique. Lymph
node status was known for 106 patients, 62 of whom were
node positive.
Assessment ofstaining
In the original publications each group adopted their own
method for scoring positive staining, but in all cases only
membrane staining was considered to be indicative of over-
expression of the c-erbB-2 protein. Positive membrane stain-
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ing was defined as coloured reaction product deliniating the
margins of tumour cells giving a 'fish-net' pattern (For
original photographs see Wright et al., 1989; Gusterson et al.,
1988; Barnes et al., 1988). Although the same antibody was
used by all groups, different methods were used to demon-
strated the antibody/antigen reaction. Before the results were
combined for statistical analysis slides of stained sections
were circulated between the participants to ensure compar-
ability of assessment. Twenty sections from each study, half
of which were deemed to be positive and half negative, were
distributed. At the same time details of the original evalua-
tions were sent to one person not involved in the primary
evaluation of staining (WJG). Each group's assessments were
sent to the assessor who collated the results.
Each set of slides was read by each of the three groups.
There was complete agreement of 27 of the 30 positively
stained sections. In the three other cases there was slight
disagreement, two groups calling them positive while the
third group thought them to be weakly positive. There was
total agreement in 29/30 of the negative cases. One group
described the remaining case as 'difficult but positive' while
the other two considered it to be negative. This was due to a
high background of non-specific staining which despite opti-
misation of the conditions occurs in a small proportion of
the cases studied. These results demonstrate only slight differ-
ences in interpretation in the assessment of immunocyto-
chemical staining. It was, therefore, considered valid to
combine the results for statistical analysis.
Statistical methods
The six variables analysed were c-erbB-2 staining (negative or
positive), grade (I, II or III) (Bloom & Richardson, 1957),
node (histologically negative or positive), oestrogen receptor
status (er, negative or positive), age and tumour size (in mm).
Of the 483 patients, 269 had full data. Survival time was
taken as the time between diagnosis and death from breast
cancer. Patients alive at the last follow-up or who died from
other causes were counted as censored observations. Relapse-
free survival time was taken as the time from diagnosis until
evidence of local recurrence or metastatic disease. Follow up
varied depending on the severity of disease, but was similar
in each centre.
Univariate analysis was by the log rank test stratified by
data set. In the stratified log rank analysis the difference in
survival for each variable is evaluated within each dataset
and the values for the three data sets are then combined
(Peto et al., 1977). Multivariate survival analysis was by the
Cox regression model stratified by data set (Gilks et al.,
1986). The standard Cox model for the hazard at time t, A
(t), is
A(t) = X0(t)exp[b1z1 + + bpzp]
where z, ... zp are the covariants (e.g. c-erbB-2), b, . .. bp are
the regression coefficients and 4(t) is the underlying hazard
rate at time t when all covariants are zero. In the stratified
Cox model the hazard function is modified to
A>(t) = A0,(t)exp[bjzj + + bpzp]
where j= 1, 2 or 3 depending on which data set (centre) is
being referred to. In other words, the underlying hazard is
allowed to vary between data sets but the covariate model is
the same for all centres. Variables were included if significant
at the 5% level using a forward stepwise approach.
In order to investigate the possible effect of missing data,
an analysis was carried out on all 483 cases, using extra
variables to indicate missing information.
Tumour size had a skew distribution so the natural log of
tumour size was used in the regression. This prevents the few
large values having a unduly large effect on the model.
Results
A summary of the data is shown in Table I.
The association of c-erbB-2 with grade, nodes, er, age and
tumour size was examined. The only significant association
(P<0.05) observed was a trend with grade, in that the
proportion of c-erbB-2 positive patients increased progres-
sively from grade I to grade III (Table II).
The stratified log rang test results are shown in Table III.
Three groups, chosen so that there were equal numbers of
patients in each group, were used for age and tumour size.
All variables other than age were statistically significant
(P<0.01) with respect to both survival and relapse free
survival.
For both endpoints, death and relapse, multivariate ana-
lyses were initially performed using all six variables, which
reduced the data set to 269 patients and 110 deaths/132
relapses. In both analyses er, age and tumour size were not
significantly prognostic (P>0.1) when the other variables
were already in the model. These variables were thus omitted
and the analyses were repeated for 363 patients (117 deaths/
163 relapses) who had data for c-erbB-2, grade and nodes
(Table IV).
A positive regression coefficient indicates that higher values
of the variable are associated with greater hazard, and there-
fore indicates a negative relation to survival. The models
indicate better survival and relapse free survival among
patients who were c-erbB-2 negative, grade I and node nega-
tive.
For both survival and relapse free survival analyses there
was little difference in the regression coefficient of c-erbB-2
whether all the 483 patients, the 363 patients with some data
or the 269 patients with full data were included in the model.
This suggests that the subjects with missing data were not
systematically different with respect to c-erbB-2 staining.
The key question to whether c-erbB-2 is equally prognostic
for both node negative and node positive patients was tested
by adding to the model a term relating to the interaction
between nodal status and c-erbB-2 status. The estimated risk
ofdying in any time interval for c-erbB-2 negative patients in
relation to c-erbB-2 positive patients was 69% among node
negative patients and 60% among node positive patients. For
relapse the equivalent figures were 79% and 55%. Although
this suggests that the prognostic effect of c-erbB-2 was slight-
ly greater for node positive patients the addition of the
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Table II Relation between grade and c-erbB-2 status (column per-
cent)
Grade
I II III Total
Negative 48 144 151 343
(84) (82) (74) (78)
c-erbB-2 Positive 9 32 53 94
(16) (18) (26) (22)
Total 57 176 204 437
The log rank test for trend on I df: X2l(trend) = 4.6 P= 0.04436 W.J. GULLICK et al.
Table III Log rank test results for death and relapse. For age, grade and tumour size the log rank test for
trend is given
Death Relapse
Variable No of No of Log rank No of log rank
patients deaths X2 df P relapses x2 df P
Age 482 140 2.90 1 0.09 216 0.001 1 0.97
c-erbB-2 483 140 11.62 1 0.0007 216 10.85 1 0.001
er 376 116 7.40 1 0.007 183 8.43 1 0.004
Grade 437 129 18.92 1 <0.0001 195 10.21 1 0.001
Nodes 404 128 20.96 1 <0.0001 183 24.78 1 <0.001
Tumour size 477 138 11.20 1 0.0008 213 8.46 1 0.004
Table IV Regression coefficients (b,) of the significant prognostic
variables in the Cox models for death and relapse
(a) Survival until death
Coefficient Standard Coeff./s.e.
Variable bi error se(b,) bi/se(b,) P
c-erbB-2 0.4605 0.2041 2.26 0.02
Grade 0.5665 0.1588 3.57 0.0003
Nodes 0.8250 0.2040 4.04 <0.0001
(b) Relapse free survival
Coefficient Standard Coeff./s.e.
Variable bi error se(b1) bi/se(bi) P
c-erbB-2 0.4709 0.1759 2.68 0.007
Grade 0.3036 0.1270 2.39 0.02
Nodes 0.8129 0.1705 4.77 <0.001
The variables were coded as follows: c-erbB-2 - 0 = negative;
I = positive. Grade - I = grade I; 2 = grade II; 3 = grade III. Nodes-
0 = negative (none); I = positive (some).
interaction gave a negligible improvement to the model
(P> 0.5 for both analyses). Thus the effects of c-erbB-2 and
nodes can be considered to be independent, as shown in
Table IV. These models are portrayed graphically in Figures
la and lb. The former shows the estimated percentage sur-
viving, plotted against time, for patients with the four possi-
ble c-erbB-2/ node combinations, each assuming grade II.
The shape of the curves reflects the selection of patients for
node status and survival as described in the Materials and
methods section. Using the bottom two lines of graph la, for
example, it is estimated that a c-erbB-2 negative, node
positive, grade II patient has a 72% probability of surviving
60 months whilst a c-erbB-2 positive, node positive, grade II
patient has a 60% probability. Figure lb is a similar graph
for relapse free survival. These figures were drawn by obtain-
ing the underlying survival curve from an unstratified model
with data set as a factor and applying the relevant coeffici-
ents from Table IV to get the estimated survival. Since grade
is in the model, the same pattern would be seen with grade I
and grade II patients.
c-erbB-2 is a significant prognostic factor for survival from
death due to breast cancer. Being c-erbB-2 negative reduces
the estimated risk of dying in any time period from breast
cancer to 63% of that for patients who are c-erbB-2 positive.
The 95% confidence interval is 42% to 94%.
Likewise c-erbB-2 is a significant prognostic factor for
relapse of breast cancer. Being c-erbB-2 negative reduces the
estimated risk of relapse in any time period to 62% of that
for patients who are c-erbB-2 positive. The 95% confidence
interval is 44% to 88%.
Discussion
Artificial expression of mutant neu or overexpression of
c-erbB-2 in rodent fibroblasts is transforming. High levels of
c-erbB-2 are common in comedo, large cell, ductal carcinoma
in situ (DCIS) which has a higher rate of growth than other
DCIS variants which do not overexpress c-erbB-2 (Van de
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Figure 1 a, Estimated survival until death by c-erbB-2 (C) and
nodes (N) for grade II patients. b, Estimated survival until
relapse by c-erbB-2 (C) and nodes (N) for grade II patients.
related with increased S-phase fraction in invasive car-
cinomas (Borg et al., 1989). It is therefore reasonable to ask
whether c-erbB-2 expression in breast cancer is associated
with short relapse free interval and survival and whether it
provides information independently of other known prognos-
tic factors.
Several studies have examined the relationship of c-erbB-2
with nodal involvement, oestrogen and progesterone receptor
status, tumour grade, stage, size and age of patient at diag-
nosis. In summary some studies did not find that c-erbB-2
overexpression was associated with nodal involvement (Sla-
mon et al., 1989; Van de Vijver et al., 1988; Wright et al.,
1989; Walker et al., 1989; Tsuda et al., 1989; Tandon et al.,
1989; Zhou et al., 1989; Barnes et al., 1988; Zhou et al.,
1987) but an almost equal number found a weak positive
relationship (Cline et al., 1987; Berger et al., 1988; Seshadri
et al., 1989; Rio et al., 1987; Guerin et al., 1989; Borg et al.,
1989). The majority of reports revealed an inverse relation-
ship with the presence of oestrogen receptors (Wright et al.,
1989; Tandon et al., 1989; Berger et al., 1988; Guerin et al.,
1989; Zeillinger et al., 1989; Borg et al., 1989) although some
others did not (Zhou et al., 1989; Barnes et al., 1988; Zhou et
al., 1987; Rio et al., 1987). Likewise, progesterone receptors
were inversely associated with c-erbB-2 in some reports (Tan-
don et al., 1989; Zeillinger et al., 1989; Borg et al., 1989) but
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not others (Zhou et al., 1989; Barnes et al., 1988; Rio et al.,
1987; Guerin et al., 1989). Increasing tumour grade has been
found to be positively associated with overexpression of
c-erbB-2 (Wright et al., 1989; Walker et al., 1989; Barnes et
al., 1988) although three studies did not demonstrate this
relation (Van de Vijver et al., 1988; Zhou et al., 1987; Guerin
et al., 1989). Evidence for (Seshadri et al., 1989; Zhou et al.,
1987; Rio et al., 1987) and against (Walker et al., 1989;
Tsuda et al., 1989; Cline et al., 1987; Zhou et al., 1989) a
positive association of c-erbB-2 with increasing tumour stage
has been presented. Tumour size has not been found to be
related (Wright et al., 1989; Walker et al., 1989; Tsuda et al.,
1989; Tandon et al., 1989; Cline et al., 1987; Zhou et al.,
1989; Seshadri et al., 1989; Zhou et al., 1987) to c-erbB-2
except in two studies (Van de Vijver et al., 1988; Borg et al.,
1989). No study has so far found an association between
c-erbB-2 and age (Van de Vijver et al., 1988; Tsuda et al.,
1989; Tandon et al., 1989; Zhou et al., 1989; Seshadri et al.,
1989; Zhou et al., 1987). In this analysis only increasing
tumour grade was positively associated with c-erbB-2 status
(P = 0.04).
If c-erbB-2 is not strongly related to other prognostic
factors, is it an independent marker of poor prognosis? Five
reports to date have not demonstrated a relation between
c-erbB-2 and short relapse free interval and survival (Cline et
al., 1987; Gusterson et al., 1988; Ali et al., 1988; Zhou et al.,
1989; Barnes et al., 1988) (average number ofpatients studied
124) while nine reports have found it prognostic (Slamon et
al., 1989; Van de Vijver et al., 1988; Wright et al., 1989;
Varley et al., 1987; Walker et al., 1989; Tsuda et al., 1989;
Tandon et al., 1989; Lovekin et al., 1989; Dolan et al., 1989)
(average number ofpatients 258). In this present study of483
cases there was a clear association between elevated c-erbB-2
protein expression and increased risk of relapse and death.
Despite a similar prevalence of overexpression of c-erbB-2
in node negative and positive patients two recent studies have
not found c-erbB-2 to be a prognostic indicator in node
negative patients having examined 181 (Slamon et al., 1989)
and 378 (Tandon et al., 1989) specimens. One possible
explanation for this finding is that the statistical power to
demonstrate an effect on survival is dependent on the number
of deaths (or relapses) in the study and patients without
involved nodes do better than those with extensive disease
(80% versus 50% 5 year survival). Even if the strength of the
effect were the same in each group, many more node negative
cases would be required to obtain a similar statistical signi-
ficance. In any case the absence of statistical significance does
not necessarily indicate that there is no effect present. How-
ever, the correct approach is not to compare P values in node
negative and positive patients but to test directly the inter-
action between c-erbB-2 status and nodal status. In the pre-
sence study we found little support for a differential effect of
c-erbB-2 between patients who were node positive and nega-
tive. Unfortunately, this analysis too has low power; a much
larger study would be needed to put the answer to this
question beyond reasonable doubt.
It will be interesting to examine whether patients with
elevated c-erbB-2 protein expression respond differently to
adjuvant chemotherapy than those without change. It may be
that the possible greater rate of cell division in those over-
expressing the growth factor receptor might increase their
response to such therapy. Studies are underway to determine
if this is indeed the case.
Thanks to Sue Ashley for providing the data from the Royal Marsden
Hospital and Diane Allen for providing the data from Guy's Hospital.
The Institute ofCancer Research issupported byfunds from theCancer
Research Campaign.
References
ALI, I.U., CAMPBELL, G., LIDEREAU, R. &CALLAHAN, R. (1988). Lack
ofevidence for the prognostic significance ofc-erbB-2 amplificaiton
in human breast carcinoma. Oncogene Res., 3, 139.
BARNES, D.M., LAMMIE, G.A., MILLIS, R.R., GULLICK, W.J., ALLEN,
D.S. & ALTMAN, D.G. (1988). An immunohistochemical evaluation
ofc-erbB-2expression in human breast carcinoma. Br. J. Cancer, 58,
448.
BERGER, M.S., LOCHER, G.W., SAURER, S. & 4 others (1988). Correla-
tion ofc-erbB-2 gene amplification and protein expression in human
breast carcinoma with nodal status and nuclear grading. Cancer
Res., 48, 1238.
BLOOM, H.I.C. & RICHARDSON, W.W. (1957). Histological grading and
prognosis in breast cancer. Br. J. Cancer, 11, 359.
BORG, A., SIGURDSSON, H., TANDON, A.K. & 4 others (1989). Proto-
oncogene amplification in human breast cancer. 1989Nordic Cancer
Union Symposium, Stockholm, abstract.
BOUCHARD, L., LAMARRE, L., TREMBLAY, P.J. & JOLICOEUR, P.
(1989). Stochastic appearance of mammary tumours in transgenic
mice carrying the MMTV/c-neu oncogene. Cell, 57, 931.
CLINE, M.J., BATTIFORA, H. & YOKOTA, J. (1987). Proto-oncogene
abnormalities in human breast cancer: correlation with anatomic
features and clinical course of disease. J. Clin. Oncol., 58, 453.
DOLAN, J., CURRAN, B., HENRY, K., LINDLEY, R. & LEADER, M.
(1989). c-erbB-2 protein expression and survival in breast car-
cinoma. J. Pathol., 158, 354A.
FALCK, V.G. & GULLICK, W.J. (1989). c-erbB-2 oncogene product
staining in gastric adenocarcinoma. An immunohistochemical
study. J. Pathol., 159, 107.
GILKS, W.R., GORE, S.M. & BRADLEY, B.A. (1986). Analysing trans-
plant survival data. Transplantation, 42, 46.
GUERIN, M., GABILLOT, M., MATHIEU, M.-C. & 4 others (1989).
Structure and expression of c-erbB-2 and EGF receptor genes in
inflammatory and non-inflammatory breast cancer: prognostic
significance. Int. J. Cancer, 43, 201.
GULLICK, W.J., BERGER, M.S., BENNETT, P.L.P., ROTHBARD, J.B. &
WATERFIELD, M.D. (1987). Expression of the c-erbB-2 protein in
normal and transformed cells. Int. J. Cancer, 40, 246.
GULLICK, W.J. & VENTER, D.J. (1989). The c-erbB-2 gene and its
expression in human tumours. In The Molecular Biology ofCancer.
Sikora, K. & Waxman, J. (eds) p. 38-53. Blackwell: Oxford UK.
GUSTERSON, B.A., MACHIN, L.G., GULLICK, W.J. & 6 others (1988).
c-erbB-2 expression in benign and malignant breast disease. Br. J.
Cancer, 58, 453.
HANKS, S.K., QUINN, A.M. & HUNTER, T. (1988). The protein kinase
family: conserved featues and deduced phylogeny of the catalytic
domains. Science, 241, 42.
LEE, J., DULL, T.J., LAX, I., SCHLESSINGER, J. & ULLRICH, A. (1989).
HER2 cytoplasmic domain generates normal mitogenic and trans-
forming signals in a chimeric receptor. EMBO J., 8, 167.
LEHVASLAIHO, H., LEHTOLA, L., SISTONEN, L. & ALITALO, K. (1989).
Achimeric EGF-R-neu proto-oncogeneallows EGFto regulateneu
tyrosine kinase and cell transformation. EMBO J., 8, 159.
LOVEKIN, C., ELLIS, I.O., LOCKER, A. & 5 others (1989). c-erbB-2
oncogene expression in breast cancer: relationships and prognostic
significance. J. Pathol., 158, 345A.
MULLER, W.J., SINN, E., PATTENGALE, P.K., WALLACE, R. & LEDER,
P. (1988). Single step induction of mammary adenocarcinoma in
transgenic mice bearing activated c-neu oncogene. Cell, 54, 105.
PETO, R., PIKE, M.C., ARMITAGE, P. & 7 others (1977). Design and
analysis ofrandomized clinical trials requiring prolonged observa-
tion ofeach patient: II analysis and examples. Br. J. Cancer, 35, 1
(especially section 22).
QUIRKE, P., PICKELS, A.,TUZI, N.L., MOHAMDEE,0. &GULLICK, W.J.
(1989). Pattern of expression of c-erbB-2 onco-protein in human
foetuses. Br. J. Cancer, 60, 64.
RIO, M.C., BELLOCQ, J.P., GAIRARD, B. & 7 others (1987). Specific
expression of the pS2 gene in subclasses of breast cancers in
comparison with expression of their estrogen and progesterone
receptors and the oncogene ERBB2. Proc. NatlAcad. Sci. USA, 84,
9243.
SESHADRI, R., MATTHEWS, C., DOBROVIC, A. & HORSFALL, D.J.
(1989). The significance ofoncogene amplification in primary breast
cancer. Int. J. Cancer, 43, 270.
SLAMON, D.J., CLARK, G.M., WONG, S.G., LEVIN, W.J., ULLRICH, A. &
McGUIRE, W.L. (1987). Human breast cancer: correlation ofrelapse
and survival with amplification of the HER-2/neu oncogene.
Science, 235, 177.
SLAMON, D.J., GODOLOPHIN, W., JONES, L.A. & 8 others (1989).
Studies of the HER2/neu proto-oncogene in human breast and
ovarian cancers. Science, 244, 707.438 W.J. GULLICK et al.
TANDON, A.K., CLARK, G.M., CHAMNESS, G.C., ULLRICH, A. &
McGUIRE, W.L. (1989). HER2/neu oncogene protein and prognosis
in breast cancer. J. Clin. Oncol., 7, 1120.
TSUDA, H., HIROHASHI, S., SHIMOSATO, Y. & 11 others (1989).
Correlation between long termsurvival in breast cancerpatientsand
amplification oftwo putativeoncogene-coamplification units: hst-1/
int-2 and c-erbB-2/ear-1. Cancer Res., 49, 3104.
VAN DE VIJVER, M.J., PETERSE, J.L., MOOI, W.J. & 4 others (1988).
neu-protein overexpression in breast cancer. N. Engl. J. Med., 319,
1239.
VARLEY, J.M., SWALLOW, J.E., BRAMMER, W.J., WHITTAKER, J.L. &
WALKER, R.A. (1987). Alterations to either c-erbB-2 (neu) or c-myc
proto-oncogenes in breast carcinomas correlate with poor short-
term prognosis. Oncogene, 1, 423.
WALKER, R.A., GULLICK, W.J. & VARLEY, J.M. (1989). An evaluation
of immunoreactivity for c-erbB-2 protein as a marker of poor
short-term prognosis in breast cancer. Br. J. Cancer, 60, 426.
WRIGHT, C., ANGUS, B., NICHOLSON, S. &6 others (1989). Expression
of c-erbB-2 oncoprotein: a prognostic indicator in breast cancer.
Cancer Res., 49, 2087.
YARDEN, Y. & WEINBERG, R.A. (1989). Experimental approaches to
hypothetical hormones: detection of a candidate ligand of the neu
proto-oncogene. Proc. Natl Acad. Sci. USA, 86, 3179.
ZEILLINGER, R., KURY, F., CZERWENKA, K. & 11 others (1989).
HER-2amplification, steroid receptorsandepidermal growth factor
receptor in primary breast cancer. Oncogene, 4, 109.
ZHOU, D.-J., AHUJA, H. & CLINE, M.J. (1989). Proto-oncogene abnor-
malities in human breast cancer: c-erbB-2 amplification does not
correlate with recurrence of disease. Oncogene, 4, 105.
ZHOU, D., BATTIFORA, H., YOKOTA, J., YAMAMOTO, T. &CLINE, M.J.
(1987). Association ofmultiplecopies ofthec-erbB-2 oncogenewith
spread of breast cancer. Cancer Res., 47, 6123.